Read this headline in order: "Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc."
The news behind $TCRT +96.19% pre-market comes after a semicolon in another company's leadership announcement. The headline is in the past tense, "Acquired." It gives no price, no structure and no share count.
That matters for a company valued at about $2M with a 3M-share float. If Alaunos paid in new stock, existing holders get diluted. If it paid in cash, the company's cash goes down. The headline does not say which.
Alaunos's own record: in 16 prior sessions that opened at least 5% above the previous close, 69% closed below their open. The median open-to-close was -6.14%.
Until the terms come out, the only thing this headline settles is the tense.